Biotech | March 21, 2022
Wockhardt and Serum Life Sciences UK partner to manufacture multiple vaccines in UK
The facility will produce 150 million vaccine doses per year
The facility will produce 150 million vaccine doses per year
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
The expansion reiterates BASF’s continued commitment to Asia Pacific and specifically to customers in the medical glove industry
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
Over the next three years, BASF will continue to support Beyond Suncare by supplying the required raw materials free of charge and by providing technical expertise to further improve the formulation
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
Subscribe To Our Newsletter & Stay Updated
